When orally administered to mice with collagen-induced arthritis it reduced the level of circulating antibodies suppressing disease and in dogs with spontaneous B cell non-Hodgkin lymphoma (NHL) treatment with the BTK inhibitor induced clinical responses [23]. Here, BTK is linked to non-Hodgkin lymphoma.